Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%

We report the first 5-year follow-up of any first-line phase III immunotherapy trial for non–small-cell lung cancer (NSCLC). KEYNOTE-024 (ClinicalTrials.gov identifier: NCT02142738) is an open-label, randomized controlled trial of pembrolizumab compared with platinum-based chemotherapy in patients w...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Reck, Martin, Rodríguez-Abreu, Delvys, Robinson, Andrew G., Hui, Rina, Csőszi, Tibor, Fülöp, Andrea, Gottfried, Maya, Peled, Nir, Tafreshi, Ali, Cuffe, Sinead, O'Brien, Mary, Rao, Suman, Hotta, Katsuyuki, Leal, Ticiana A., Riess, Jonathan W., Jensen, Erin, Zhao, Bin, Pietanza, M. Catherine, Brahmer, Julie R.
Formato: Artigo
Idioma:Inglês
Publicado em: Wolters Kluwer Health 2021
Assuntos:
RAPID COMMUNICATIONS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8280089/
https://ncbi.nlm.nih.gov/pubmed/33872070
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.21.00174
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados